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Abstract
Inflammatory bowel diseases (IBDs) are lifelong disorders predominantly present
in developed countries. In their pathogenesis, an interaction between genetic
and environmental factors is involved. This practice guide, prepared on behalf
of the European Society of Pathology and the European Crohn's and Colitis
Organisation, intends to provide a thorough basis for the histological evaluation
of resection specimens and biopsy samples from patients with ulcerative colitis
or Crohn's disease. Histopathologically, these diseases are characterised by the
extent and the distribution of mucosal architectural abnormality, the cellularity
of the lamina propria and the cell types present, but these features frequently
overlap. If a definitive diagnosis is not possible, the term indeterminate colitis
is used for resection specimens and the term inflammatory bowel disease
unclassified for biopsies. Activity of disease is reflected by neutrophil granulocyte
infiltration and epithelial damage. The e...
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Abstract Inflammatory bowel diseases (IBDs) are lifelong
disorders predominantly present in developed countries. In
their pathogenesis, an interaction between genetic and envi-
ronmental factors is involved. This practice guide, prepared on
behalf of the European Society of Pathology and the European
Crohn’s and Colitis Organisation, intends to provide a thor-
ough basis for the histological evaluation of resection speci-
mens and biopsy samples from patients with ulcerative colitis
or Crohn’s disease. Histopathologically, these diseases are
characterised by the extent and the distribution of mucosal
architectural abnormality, the cellularity of the lamina propria
and the cell types present, but these features frequently over-
lap. If a definitive diagnosis is not possible, the term indeter-
minate colitis is used for resection specimens and the term
inflammatory bowel disease unclassified for biopsies. Activity
of disease is reflected by neutrophil granulocyte infiltration
On behalf of the European Society of Pathology (ESP) and the European
Crohn’s and Colitis Organisation (ECCO).
C. Langner (*)
Institute of Pathology, Medical University of Graz,
Auenbruggerplatz 25, 8036 Graz, Austria
e-mail: cord.langner@medunigraz.at
F. Magro
Department of Gastroenterology,
Hospital de Sao Joao,
Rua José da Silva Passos 48, 4240-044 Porto, Portugal
A. Driessen
Department of Pathology, University Hospital Antwerp,Wilrijkstraat
10, 2650 Edegem, Belgium
A. Ensari
Department of Pathology, Ankara University Medical School,
Sihhiye 06100, Ankara, Turkey
G. J. Mantzaris
A’ Department of Gastroenterology, Evangelismos Hospital,
45-47 Ypsilantou Street, 10676 Athens, Greece
V. Villanacci
Institute of Pathology, Spedali Civili,
Piazzale Spedali Civili, 1, 25100 Brescia, Italy
G. Becheanu
Department of Pathology, Carol Davila University of Medicine and
Pharmacy, Bucharest, Romania
P. Borralho Nunes
Instituto de Anatomia Patologica, Escola Superior de Tecnologia da
Saúde de Lisboa & Faculdade de Medicina da Universidade de
Lisboa, Av. D. João II, Lote 4.69.01, 1990-096 Lisbon, Portugal
G. Cathomas
Institute for Pathology, Kantonsspital Baselland, Mühlemattstrasse
11, 4410 Liestal, Switzerland
W. Fries
Dip di Medicina Interna e Terapia Medica U.O. Malattie di Fegato e
dell’Apparato Digerente, Università di Messina Azienda Policlinico
Universitario, Pad. C–III piano, Via C. Valeria 1, 98100 Messina,
Italy
A. Jouret-Mourin
Department of Pathology,
Cliniques Universitaires St Luc, UCL,
Avenue Hippocrate 10, 1200 Brussels, Belgium
C. Mescoli
Department of Medicine (DIMED), Surgical Pathology and
Cytopathology Unit, University of Padua, Padua, Italy
G. de Petris
Department of Pathology and Laboratory Medicine, Mayo Clinic
Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
Virchows Arch (2014) 464:511–527
DOI 10.1007/s00428-014-1543-4
Cord Langner & Fernando Magro & Ann Driessen & Arzu Ensari & Gerassimos J. Mantzaris &
Vincenzo Villanacci & Gabriel Becheanu & Paula Borralho Nunes & Gieri Cathomas &
Walter Fries &Anne Jouret-Mourin &ClaudiaMescoli &Giovanni de Petris &Carlos A. Rubio &
Neil A. Shepherd & Michael Vieth & Rami Eliakim & Karel Geboes
and epithelial damage. The evolution of the histological fea-
tures that are useful for diagnosis is time- and disease-activity
dependent: early disease and long-standing disease show dif-
ferent microscopic aspects. Likewise, the histopathology of
childhood-onset IBD is distinctly different from adult-onset
IBD. In the differential diagnosis of severe colitis refractory to
immunosuppressive therapy, reactivation of latent cytomega-
lovirus (CMV) infection should be considered and CMV
should be tested for in all patients. Finally, patients with
longstanding IBD have an increased risk for the development
of adenocarcinoma. Dysplasia is the universally used marker
of an increased cancer risk, but inter-observer agreement is
poor for the categories low-grade dysplasia and indefinite for
dysplasia. A diagnosis of dysplasia should not be made by a
single pathologist but needs to be confirmed by a pathologist
with expertise in gastrointestinal pathology.
Keywords Inflammatory bowel disease . Ulcerative colitis .
Crohn’s disease . Consensus . Practice guidelines
Introduction
Inflammatory bowel diseases (IBDs) are lifelong disorders
that are predominantly observed in developed countries. In
their pathogenesis, an interaction between genetic and envi-
ronmental factors is involved. The term IBD was initially
coined to cover two specific diseases: ulcerative colitis (UC)
and Crohn’s disease (CD). In a broader sense, it is nowadays
also in use for other forms of chronic colitis, such as
microscopic colitis (including lymphocytic and collagenous
colitis), but these are not discussed in this review.
The intention of the Consensus, which was supported by
the European Society of Pathology (ESP) and the European
Crohn’s and Colitis Organisation (ECCO) was to address
different aspects of histological diagnosis in IBD: (1) proce-
dures required for a proper diagnosis, (2) features that can be
used for making a diagnosis on endoscopic biopsies, (3)
features that can be used for making a diagnosis on surgical
specimens, (4) criteria that establish a diagnosis or a differen-
tial diagnosis (how many features should be present for a firm
diagnosis), (5) impact of therapy on IBD histopathology, (6)
criteria to diagnose and grade dysplasia and (7) features de-
fining disease activity.
The Consensus paper, which is based on previous evi-
dence-based ECCO Consensus publications [1, 2], was re-
cently published in the Journal of Crohn’s and Colitis [3]. The
paper summarises the Consensus statements, followed by
comments on evidence and opinion with specific emphasis
on the clinicopathological interface, e.g. technical procedures
necessary for accurate diagnosis of IBD on endoscopic biop-
sies (number and handling of biopsies, etc.). It also provides
detailed information regarding the strategy and the methods
used for the development of the evidence-based guidelines.
The aim of this paper is to provide a solid basis for the
histopathological diagnosis of UC and CD on both resection
specimens and biopsy samples: It focusses on the histological
criteria for diagnosis and differential diagnosis and contains
illustrative images. The content of the present and the previous
[3] publication was approved by all participants in the con-
sensus meetings.
Procedures for the diagnosis of IBD
The histological examination of endoscopic biopsies or resec-
tion specimens is a crucial element in the diagnostic work-up
of a patient with suspected IBD and assists in making a final
diagnosis, particularly in differentiating between UC and CD
and other forms of colitis. However, IBD is a clinical diagno-
sis and, as such, is based upon clinical information, endoscop-
ic findings and morphological features observed in biopsies,
as well as data from laboratory and imaging procedures. Thus,
for a correct interpretation of biopsy specimens from patients
with suspected IBD, detailed clinical information is essential.
In patients with suspected IBD, histological examination
should be performed before initiation of treatment because
drug treatment can induce changes in morphology. Since
lesions may be focal, multiple sections from each tissue sam-
ple should be examined. In order to detect mild or focal lesions
and to increase diagnostic accuracy, serial sectioning of biopsy
specimens is superior to step sectioning, and the diagnostic
yield increases with the number of sections examined [4–6].
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However, the optimal number of sections to be examined in
daily practice has not been established, the numbers varying
between two and six in different studies [6, 7]. For daily
practice, we recommend step-sections with two or three tissue
levels, each consisting of five or more sections [8]. Staining
with haematoxylin and eosin (H&E) suffices for a diagnosis,
and special stains, including immunohistochemistry, are not
needed.
The pathology report in all cases of chronic colitis should
give an indication of disease activity, as reflected in the extent
of neutrophil granulocyte infiltration and epithelial damage. In
cases of UC, a distinction should be made between quiescent
disease, inactive disease and active disease, and the latter
should be graded. This has led to the introduction of scoring
systems for the assessment of disease activity in UC, and these
are used in clinical drug trials [9]. In CD, there is less evidence
supporting the validity of histological grading of disease ac-
tivity, but data from recent drug trials indicate that patients
showing mucosal healing have a better outcome [10, 11]. In
CD, inactivity in a biopsy may not reflect inactivity of IBD
because of the discontinuous and transmural character of the
disease, which induces sampling error, and also because as a
rule biopsy samples of the ileum are limited, whereas the
ileum may be the only bowel segment involved.
A surgical specimen requires systematic protocolled gross
examination, with photographic documentation prior to fixa-
tion, as soon as the specimen is removed. Specimens should
be opened longitudinally along the antimesenteric or
antimesocolic side, except when a carcinoma is suspected, in
which case it is advisable to leave a small segment unopened
during fixation. Macroscopic aspects that constitute potential
diagnostic features [13, 14], including transmural extension
and fistulas, should be recorded. Special attention should be
paid to lesions suspicious for neoplasia. Tissue samples for
microscopy should include lymph nodes, terminal ileum and
appendix. An optimal number of samples has not been
established, but multiple samples, both from affected mucosa
and macroscopically normal mucosa, improves the diagnostic
yield. Burroughs and Williams [12] recommended that one
section should be taken per 10 cm of resected bowel, in
addition to sampling of any lesion. The site of a tissue sample
should be recorded, e.g. by stating its distance to a specified
resection margin.
Ulcerative colitis
Macroscopy
Gross examination of a resection specimen in UC classically
shows diffuse and continuous chronic inflammation without
skip lesions, which involves the rectum and spreads proximal-
ly with gradually decreasing severity of inflammation
(Table 1). The transition between the involved and the normal
mucosa is sharp (Fig. 1a). The mucosa has a friable granular
appearance and shows superficial ulcers (Fig. 1b). In severe
disease, these ulcers may undermine the adjacent mucosa,
finally resulting in denudation of the mucosal surface or deep
penetration through the muscularis mucosae [15, 16].
Extensive ulceration with sparing of remaining mucosal
islands may give rise to inflammatory polyps, which are
common in the sigmoid and descending colon but rare in the
rectum (Fig. 1c). In fulminant colitis, the macroscopic appear-
ance of the mucosa is not sufficiently distinct to differentiate
UC from CD [17, 18] and serositis may be observed [19].
Ulcerative colitis Crohn’s disease
Localisation GI tract Especially colon Whole GI tract
Ileum Not except in backwash ileitis Often involved
Colon Left>right Right>left
Rectum Commonly involved Typically spared
Distribution GI tract Diffuse (continuous) Segmental (discontinuous)
Ulcers Superficial ulcers Aphthous ulcers, confluent deep linear ulcers
Inflammatory polyps Common Uncommon
Skip-lesions Absent Present
Cobblestone pattern Absent Present
Deep fissures Absent except in fulminant colitis Present
Fistulae Absent except in fulminant colitis Present
Mucosal atrophy Marked Minimal
Thickness of the wall Normal Increased
Fat wrapping Absent Present
Strictures Uncommon Present
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Table 1 Macroscopic features for
the diagnosis of inflammatory
bowel disease
Awareness of unusual macroscopic distribution patterns,
such as rectal sparing, caecal patch and backwash ileitis is
important to avoid diagnostic errors. The rectum may be
spared in untreated children (30 %), adults with fulminant
colitis (13 %) or patients receiving topical and/or systemic
treatment (44 %) [18, 20–23]. Another therapy-related finding
is patchiness, i.e. discontinuous rather than continuous inflam-
mation [20, 23]. When left-sided colitis is associated with
inflammation surrounding the appendiceal orifice, this is
called ‘caecal patch’. Such discontinuous periappendiceal in-
flammation has been diagnosed in up to 75 % of patients with
distal disease [24–26]. Backwash ileitis occurs in approxi-
mately 20 % of patients with pancolitis. It has rarely been
described as primary ileal inflammation in patients with sub-
total or left-sided colitis only [27]. This finding, however,
needs further validation, particularly as it is difficult to
Fig. 1 Gross examination of a
resection specimen in ulcerative
colitis classically shows diffuse
and continuous chronic
inflammation, with a sharp
transition between the involved
and the normal mucosa (a). The
mucosa has a friable granular
appearance and shows superficial
ulcers (b). Extensive ulceration
with sparing of remaining
mucosal islands gives rise to
inflammatory polyps (c). Long
standing disease with atrophic
mucosa lacking mucosal
haustration and adenocarcinoma
(arrows) within a stricture (d)
Table 2 Microscopic features
used for the diagnosis of inflam-
matory bowel disease
Ulcerative colitis Crohn’s disease
Crypt architectural irregularity Diffuse (continuous) Focal (discontinuous)
Chronic inflammation Diffuse (continuous) Focal (discontinuous)
Decrease proximally Variable
Patchiness Uncommon Common
Localisation of inflammation Transmucosal Transmural
Sometimes in submucosa
Serositis Absent except in fulminant colitis Present
Lymphoid aggregates Frequent in mucosa, submucosa Common, transmural
Granulomas Absent, except with ruptured crypts Common
Acute inflammation Diffuse (continuous) Focal (discontinuous)
Crypt epithelial polymorphs Diffuse (continuous) Focal (discontinuous)
Crypt abscesses Common Uncommon
Mucin depletion Present, pronounced Uncommon, mild
Neuronal hyperplasia Rare Common
Muscular hypertrophy Absent Present
Paneth cell metaplasia Present Uncommon
Pyloric gland metaplasia Rare Present
514 Virchows Arch (2014) 464:511–527
distinguish from Crohn’s terminal ileitis [28, 29]. In
longstanding UC, tissue repair is associated with fibrosis,
which, in contrast to CD, is commonly restricted to mucosa
or submucosa. This fibrosis rarely causes benign strictures
(3.2–11.2 %), which have to be differentiated from tumour-
related stenoses (Fig. 1d) [30]. In the quiescent phase of the
disease, mucosal haustration disappears, resulting in an atro-
phic smooth mucosa.
Histology
The histological diagnosis of UC is based upon four main
categories of features: mucosal architecture, lamina propria
cellularity, neutrophil granulocyte infiltration, and epithelial
abnormality (Table 2). Awareness of the normal range of
appearances of colorectal mucosa is necessary for optimal
interpretation of biopsy specimens [31].
The assessment of abnormal lamina propria cellularity in
UC refers to increased and/or altered distribution of cell types
normally present in the colorectal mucosa. Apart from areas of
frank ulceration, the inflammatory infiltrate in untreated dis-
ease is limited to the mucosa, diffuse or continuous without
any variations in intensity or skip lesions, and its severity
increases characteristically towards the rectum [32, 33]. A
homogeneous increase in cellularity occurs throughout the
lamina propria, for which the term transmucosal is used, and
this can be best appreciated in the lower third, which has the
lowest cell density in normal mucosa (Fig. 2a, b) [31].
Plasma cells are predominantly observed between the base
of the crypts and the muscularis mucosae (basal
plasmacytosis) (Fig. 2c). This feature is helpful in differenti-
ating between a first attack of UC (63 %) and infectious colitis
(6 %), but not CD (62 %) [8, 34]. Neutrophils, which reflect
disease activity, are present in the lamina propria and/or
Fig. 2 Diffuse (continuous)
inflammation with basal
plasmacytosis, yet onlymild crypt
atrophy (shortening or ‘gland lift-
off’) in early stage ulcerative
colitis (a, original magnification,
×100), compared to marked crypt
architectural distortion with crypt
branching in longstanding disease
(b, original magnification, ×75).
Plasma cells are predominantly
observed between the base of the
crypts and the muscularis
mucosae (‘basal plasmacytosis’)
(c, original magnification, ×400).
Disease activity is indicated by
cryptitis and crypt abscess
formation, which may lead to
crypt destruction with a
granulomatous reaction
(‘cryptolytic granuloma’), which
should not be mistaken as
diagnostic feature of Crohn’s
disease (d, original magnification,
×250). Patchiness of
inflammation in longstanding
disease (e, original magnification,
×150). Marked crypt architectural
distortion and hypocellular
stroma in quiescent disease (f,
original magnification, ×150)
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invade the surface or crypt epithelium, resulting in cryptitis
(presence of neutrophils within crypt epithelium) or crypt
abscesses (presence of neutrophils within crypt lumina).
Crypt abscesses are more common in UC (41 %) than in CD
(19 %) [31]. The number of eosinophils is variable.
Granulomas are not observed, except for those in response
to foreign bodies or to mucin from ruptured crypts (cryptolytic
granulomas) (Fig. 2d) [35].
Alterations in mucosal architecture due to chronic inflam-
mation are reflected in crypt architectural abnormalities (dis-
tortion, branching and atrophy), decreased crypt density (sep-
aration of adjacent crypts by lamina propria equivalent to or
greater than one crypt diameter) and changes of surface to-
pography (surface irregularity) [31]. Normal crypts are
straight, parallel and extend from immediately above the
muscularis mucosae to the surface.
Crypt distortion implies crypts that are no longer parallel,
vary in diameter and/or are dilated (Fig. 2b). Crypt branching
represents regeneration through fission: branching of more
than 10 % of crypts or presence of more than two branched
crypts in a well-oriented biopsy specimen with at least 2 mm
of muscularis mucosase is abnormal [7, 31]. Crypt atrophy is
defined as shortened crypts, accompanied by an increased
layer of lamina propria stroma between the crypt basis and
the muscularis mucosae [31]. In UC, distorted crypt architec-
ture with crypt branching and atrophy is present in 57–100 %
of cases, and irregular villiform architecture in 17–30 % of
cases, more frequently than in CD (27–71 % and 12 %,
respectively) [8, 31, 34, 36].
Epithelial abnormalities include surface epithelial damage,
mucin depletion, and metaplastic changes [28]. Surface epi-
thelial damage, such as flattening, focal cell loss, erosions, and
ulcers reflect the activity of disease. Mucin depletion, defined
as reduction in the number of goblet cells and/or reduced
quantity of intracellular mucin, is a weak diagnostic feature
in UC as it also occurs in other reactive processes, such as
infectious colitis and CD [4, 34, 37]. Paneth cell metaplasia (in
the left colon), inflammatory polyps, hypertrophy of the
muscularis mucosae, and the much less frequently observed
submucosal fibrosis are additional features of chronicity [38].
In early stage disease, the diagnosis of UC can be chal-
lenging. Preserved crypt architecture and absence of a
transmucosal inflammatory infiltrate do not rule out early
stage UC, in which case the distinction from infectious colitis
(acute self-limiting colitis) is a major concern [39]. Its histo-
logical features are not diagnostic, and up to 30 % of patients
with this pattern will eventually progress towards IBD [40].
Focal or diffuse basal plasmacytosis is the earliest diagnostic
feature with the highest predictive value for diagnosis and can
be identified in 38 % of patients within 2 weeks after presen-
tation [41].
In longstanding disease, there is widespread architectural
crypt distortion and increased cellularity of the lamina propria.
In this situation, confusing features occur such as patches of
normal mucosa, discontinuous inflammation and rectal spar-
ing. This needs to be kept in mind to avoid misdiagnosis, such
as changing a diagnosis of UC into CD. With time, (under
treatment), the extent of involvement of the colon tends to
decrease, ultimately resulting in complete restoration of the
rectal mucosa in 34–44 % of patients. In parallel, the distri-
bution pattern may change from diffuse (continuous) to
patchy (discontinuous) (Fig. 2e) [20, 32, 42], with or without
treatment [43]. This type of histological evolution may result
in diagnostic dilemmas, in particular when clinical informa-
tion is not available [44]. As discontinuity and patchiness are
both features characteristic for CD, the accuracy of the initial
diagnosis of UC may erroneously be questioned, particularly
in the absence of information on treatment.
In (clinically) quiescent disease, the mucosa may still
show features, which reflect sustained damage, such as
architectural abnormalities and reduced crypt density
[45]. During regeneration, the mucin content of goblet
cells is restored [46]. The inflammatory infiltrate is of
variable density, and as a result, the lamina propria may
either appear hyper- or hypocellular (Fig. 2f). Neutrophils
are not observed in quiescent disease, but the number of
eosinophils does not change [47]. Ultimately, basal
plasmacytosis decreases resulting in normal cellularity of
the lamina propria. Histological findings predictive of en-
suing clinical relapse in patients with quiescent disease are
persistence of basal plasmacytosis, mildly active disease or
a high number of eosinophils [41, 48, 49].
Pouchitis
Proctocolectomy with ileal pouch anal anastomosis (IPAA) is
the procedure of choice for most patients with UC requiring
colectomy. ‘Pouchitis’ refers to active inflammation of IPAA
mucosa and is considered as a primary ‘non-specific, idio-
pathic inflammation of the neorectal ileal mucosa’ [50, 51].
Three to 20 % of patients develop persistent or recurrent
episodes of pouchitis, which, based upon the duration of
symptoms, may be acute (<4 weeks) or chronic (>4 weeks).
While in patients with acute pouchitis antibiotic therapy is
usually effective, approximately 10–15 % of these patients
develop chronic pouchitis, refractory to this treatment
(chronic refractory pouchitis) [52]. Some patients may de-
velop CD-like complications including perianal fistulas and
inflammation, stenoses or fistulas in the pre-pouch ileum
and/or the pouch. The diagnosis of pouchitis is based on a
combination of clinical symptoms, endoscopic and histo-
logical findings. Histological changes may be patchy and
more prominent in the lower and posterior regions of the
pouch. Consequently, multiple biopsies from these sites are
essential for the diagnosis [53].
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Chronic inflammatory changes, present in up to 87 % of
biopsies from ‘healthy’ pouches, consist of architectural dis-
tortion, villous atrophy, crypt hyperplasia and infiltration of
the lamina propria by mononuclear cells, eosinophils and
histiocytes. Neutrophils are rarely present. Villous atrophy
and crypt hyperplasia are considered adaptive changes (‘co-
lonic’ metaplasia). Mild ischaemic changes occasionally oc-
cur, while some patients develop features of mucosal prolapse,
most often in the anterior wall. In pouchitis, patchy
intraepithelial neutrophil infiltrates become more numerous
and cryptitis ensues, with crypt abscesses and ulcerations
(Fig. 3a). As colonic metaplasia occurs more frequently in
cases with pouchitis, it may be a reparative rather than an
adaptive response [54].
The histology of chronic refractory pouchitis is mostly
identical to that of ‘usual’ pouchitis. In this situation, other
possible causes such as infections [particularly cytomegalovi-
rus (CMV)] should be considered. The development of CD-
like complications in chronic pouchitis may cast doubt on the
initial diagnosis. Biopsy specimens usually show features of
severe inflammation with neutrophils within the lamina
propria and invading the epithelium, resulting in erosions,
ulcerations and mucosal architectural distortion (Fig. 3b).
Histology of pouches excised for these complications may
show deep submucosal lymphoid aggregates and granulation
tissue-lined fistulous tracts. Similar changes, and even granu-
lomas, have been observed in blind ending rectal stumps left
in situ after total colectomy for UC [55]. The occurrence of
CD-like complications and the presence of deeply situated
lymphoid aggregates do not refute a diagnosis of UC. CD
should only be diagnosed after IPAA surgery when re-
examination of the original proctocolectomy specimen shows
typical features of CD [56]. Pyloric gland metaplasia is asso-
ciated with chronic mucosal damage and can be encountered
not only in UC but also due to trauma, prolapse, non-steroidal
anti-inflammatory drug-induced injury and CD [57].
Crohn’s disease
Macroscopy
CD can affect any part of the gastrointestinal tract, but it
occurs most commonly in the terminal ileum, often in associ-
ation with the right colon (Table 1). Isolated large bowel
involvement occurs in approximately 20 % of cases, prefer-
entially in the right colon. Warren [58] distinguished three
basic patterns of large bowel involvement: CD limited to the
rectum, stenosing large bowel CD and diffuse Crohn’s colitis
typically with reduced involvement of the rectum.
Approximately 75 % of patients with large bowel CD at some
point during the course of the disease develop perianal man-
ifestations, including skin tags, deep ulcers, fissures, fistulae,
abscesses, blind sinus tracts and strictures [58].
Characteristically, macroscopic examination of a resection
specimen with CD shows a discontinuous pattern of inflam-
mation. Diseased segments are frequently separated by areas
of uninvolved, i.e. normal, bowel (skip lesions) (Fig. 4a) and
transition from involved to uninvolved areas is usually abrupt.
The serosal surface of an involved bowel segment is often
hyperaemic and may be covered with inflammatory exudate,
but in longstanding cases, serosal adhesions occur. Mainly in
small bowel CD, but less frequently also in large bowel CD
adipose tissue expands towards the antimesenteric surface,
which is called ‘fat wrapping’. Fat wrapping is a valuable
diagnostic criterium for the diagnosis of CD [59], and it also
occurs in segmental colitis associated with diverticulosis,
along with other Crohn’s colitis-like changes (such as fissur-
ing ulcers, granulomas and transmural lymphoid aggregates)
[60, 61].
The earliest grossly visible mucosal lesions are small
aphthous ulcers that typically develop over lymphoid follicles
along the mesenteric margin of the bowel wall [62] and are
bordered by quite normal mucosa (Fig. 4b). As aphthous
Fig. 3 Pouchitis with patchy infiltration of the lamina propria and the
surface epithelium by neutrophils causing aphthous erosion (a, original
magnification, ×150). In refractory disease, severe inflammation with
increased lamina propria cellularity, presence of neutrophils within
lamina propria and epithelium, Crohn’s-like fissures and mucosal archi-
tectural distortion may be observed together with crypt hyperplasia and
villous atrophy (colonic metaplasia) (b, original magnification, ×75)
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ulcers coalesce, they form large deep serpiginous or linear
ulcers with overhanging oedematous mucosal edges (Fig. 4c).
Islands of oedematous, non-ulcerated mucosa, separated by
deep discrete ulcers, give rise to the classic cobblestone ap-
pearance. As inUC, inflammatory polyps occur. Healed ulcers
leave depressed scars.
Fistulae are a common finding in small bowel CD.
Although relatively rare, they occur also in CD in the colon,
mainly in patients with ileocolitis. Free perforation, however,
is exceptional. At sites of transmural inflammation with fibro-
sis and fibromuscular proliferation, the bowel wall becomes
thickened and increasingly rigid (Fig. 4d). Strictures ensue,
more often in the small than in the large intestine.
Histology
Avariety of microscopic features support the diagnosis of CD
(Table 2). Focal (discontinuous) chronic inflammation, focal
crypt architectural distortion and granulomas not related to
crypt injury are the features with highest diagnostic value.
These, as well as an irregular villous architecture, are features
in favour of a diagnosis of CD in endoscopic ileal biopsy
samples.When the ileitis is in continuity with proximal colitis,
the features should be used with caution, because they occur
also in backwash ileitis in UC.
Focal (discontinuous) chronic inflammation implies in-
creased cellularity of the lamina propria (with lymphocytes
and plasma cells), of variable density throughout the biopsy
specimen and not confined to the superficial mucosa. One or
more circumscript foci with increased mononuclear cell den-
sity with or without infiltration of neutrophils will be found,
against a background of normal mucosa or mucosal samples
with variable intensity of inflammation. Normal lymphoid
aggregates are not considered as focal inflammation.
Assessment of differences in cellularity between multiple
biopsy specimens is more reproducible than differences with-
in a single biopsy specimen. In a biopsy, the inflammation
may extend into the submucosa. As in UC, the presence of
neutrophils in the lamina propria or in the epithelium, includ-
ing cryptitis and crypt abscesses, indicates active disease and
signifies epithelial damage (Fig. 5a, b).
An epithelioid cell granuloma is a discrete collection of
at least five epithelioid cells (activated histiocytes with
homogeneous slightly eosinophilic cytoplasm), with or
without multinucleated giant cells [31]. In CD, granulo-
mas are often poorly delimited. Multinucleated giant cells
may be absent and necrosis is unusual. Only granulomas
not related to crypt injury should be regarded as a feature
in support of CD (Fig. 5c) [35]. Notably, non-caseating
granulomas, small collections of epithelioid histiocytes
with giant cells or isolated giant cells, occur also in
infectious colitis (acute self-limiting colitis), parasitic in-
fections and intestinal tuberculosis and should not be
regarded as evidence in favour of CD.
As in UC, the chronic inflammatory process induces alter-
ations in mucosal architecture. These are generally less prom-
inent than in UC and focal or discontinuous. Pyloric gland
metaplasia is related to mucosal ulceration and repair [63] and
Fig. 4 Gross examination of a
resection specimen in Crohn’s
disease classically shows a
discontinuous pattern of
inflammation (skip lesions).
Mainly in the small bowel,
adipose tissue expanding towards
the antimesenteric surface may be
observed (‘fat wrapping’, arrow)
(a). The earliest grossly visible
mucosal lesions are small
aphthous ulcers that typically
develop over lymphoid follicles
(b). As the aphthous ulcers
enlarge, they coalesce to large
deep serpiginous or linear ulcers
with overhanging oedematous
mucosal edges (c). At sites of
transmural inflammation with
fibrosis and fibromuscular
proliferation the bowel wall may
become thickened and strictures
may develop; prominent fat
wrapping is seen as secondary
finding (arrows) (d)
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is observed in 2–27 % of ileal biopsies from patients with CD
but very common in ileal resection specimens (Fig. 5d). It has
been rarely described in resection specimens with backwash
ileitis in UC, only in combination with active ileal inflamma-
tion and/or ulceration [27] but not in ileal biopsies from
patients with UC [28, 29, 64].
Transmural lymphoid aggregates (identifiable only in re-
section specimens and usually not in ulcerated areas) and
granulomas are features supporting a diagnosis of CD. In a
study on colectomy specimens from cases with fulminant
colitis, granulomas and lymphoid aggregates proved to be
the two most specific predictors of a final diagnosis of CD
[18].
When only a single feature is present, this is not regarded as
sufficient for a reliable diagnosis of CD. Most expert clini-
cians and pathologists agree that the presence of granulomas
and at least one other feature establishes a diagnosis of CD
[65]. The second feature can be either inflammation or, more
specifically, architectural abnormalities. While focal architec-
tural abnormalities favour CD, a pseudovillous appearance of
the colorectal mucosal surface is more consistent with a diag-
nosis of UC. The presence of granulomas is not a prerequisite
for a diagnosis of CD. Granulomas are more often observed in
children and adolescents than in adults. Additional useful
features are focal chronic inflammation without crypt atrophy,
focal cryptitis (although with poor reproducibility [66–68]),
aphthous ulcers, disproportionate submucosal inflammation,
neural hypertrophy (nerve fibre hyperplasia [13, 69]), in-
creased number of intraepithelial lymphocytes [68] and in
the colon proximal location of ulceration and architectural
distortion. When multiple biopsies are available, ileal involve-
ment, colonic inflammation with a decreasing proximal to
distal gradient, as well as the absence of features highly
suggestive or diagnostic for UC, such as diffuse inflammation,
crypt irregularity and reduced crypt density, also support a
diagnosis of CD. Particularly in children and adolescents,
Fig. 5 Focal (discontinuous)
mucosal inflammation in Crohn’s
colitis (a, original magnification,
×150) with fissuring ulceration (b,
original magnification, ×100) and
vaguely defined epithelioid cell
granuloma not related to crypt
injury (c, original
magnification,×400). Pyloric
gland metaplasia in chronic ileitis
(d, original magnification, ×150).
Involvement of the upper
gastrointestinal tract in Crohn’s
disease with focally enhanced
gastritis (e, arrows, original
magnification,×100) and
duodenitis (f, original
magnification, ×100)
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biopsies from the upper gastrointestinal tract can provide
additional diagnostic clues.
Indeterminate and unclassified colitis
In approximately 5 % of IBD cases, a definite diagnosis of UC
or CD cannot be established, most often due to either insuffi-
cient clinical, radiologic, endoscopic or pathological data, or
overlapping features of both disorders [70]. Labels such as
‘indeterminate colitis’, ‘inflammatory bowel disease unclassi-
fied (IBDU)’, ‘chronic inflammatory bowel disease unclassi-
fied’ and ‘chronic idiopathic inflammatory bowel disease not
otherwise specified’ are in use for such cases.
The term ‘indeterminate colitis’ (IC) was first introduced in
1970 by Kent et al. [71] in a study on colectomy specimens of
patients with IBD with overlapping features of UC and CD. It
is probably the most commonly used terminology, but a
universally accepted definition for this label has not been
established. The introduction of endoscopy with endoscopic
biopsy changed clinical management and the pathologist’s
perception. Subsequently, the term IC was increasingly used
also for patients presenting with clinical features of chronic
IBD, with inflammation restricted to the colon and no small
bowel involvement, when endoscopy was non-conclusive and
diagnostic features for either CD or UC were absent on
biopsies while infectious colitis and other causes of colitis
had been excluded.
As a consequence, IC signifies diagnostic uncertainty as to
whether a patient has UC or CD and a diagnosis of IC on
endoscopic biopsies is not based upon specific histological
features [68, 72]. To solve the problem of the ambiguous
significance of the term IC, the working party of the 2005
MontrealWorld Congress of Gastroenterology and the pathol-
ogy task force of the International Organization for
Inflammatory Bowel disease attempted to clarify a definition
[73, 74]. The ESP/ECCO working group for the European
Consensus in pathological findings in IBD equally favours an
agreement on terminology, in order to allow comparison be-
tween different studies.
The term IC should be restricted to cases in which com-
prehensive histological examination of (a) surgical speci-
men(s) is possible. The term IC should be avoided on endo-
scopic (preoperative) biopsies, on which the term IBDU is
preferred when a patient with chronic colitis clearly has IBD
based upon the clinical history, but macroscopy and/or endo-
scopic biopsies show no definitive features of either UC or
CD. The arguments underpinning this proposal are as follows:
1. As originally proposed, the term IC was originally pro-
posed for colectomy specimens.
2. Some diagnostic microscopic features cannot be assessed
on endoscopic biopsy samples.
3. There are no generally accepted positive histological fea-
tures for a diagnosis of IC on endoscopic samples.
4. Post-operative examination of resection specimens in
such cases usually provides definitive evidence of UC or
CD [75, 76].
Both IC and IBDU are ‘temporary diagnoses’. Diagnostic
uncertainty occurs more often in children. However, a histo-
logical pattern of non-diffuse acute and chronic inflammation
with architectural changes confined to the colon, not allowing
a final diagnosis, can also be observed in adults as part of the
natural history of UC or secondary to treatment [20, 32].
Epidemiological studies have shown that most cases with
uncertain diagnosis behave like UC [72].
Children and adolescents
IBD is an important cause of gastrointestinal pathology in
children and adolescents. About 10–15 % of patients are
diagnosed before the age of 18 years [77]. Paediatric-onset
IBD is distinctly different from adult-onset IBD, which may
hamper a diagnosis with as a result delayed or inadequate
therapy. The gold standard for diagnosing paediatric IBD
remains endoscopic evaluation of the upper and lower gastro-
intestinal tract, with mucosal biopsies for histopathological
confirmation [78–80].
Children with untreated UC commonly present with sub-
total or extensive colitis, but with less severe inflammation,
less epithelial injury and less architectural abnormalities than
UC in adults [21, 22, 77, 80–82]. Backwash ileitis occurs with
similar frequency [83], but children more often present with
unusual histologic inflammation patterns, such as patchiness
(21%) and (relative) rectal sparing (30%) [21, 22, 84]. As
children approach adulthood, the degree of inflammation and
architectural distortion approaches that found in adults.
However, in rectal biopsies, a similar degree of inflammation
is seen regardless of age group [81, 82].
At onset, CD in children is associated with more colitis and
less ileitis [85]. When the disease is severe, all biopsies
obtained during a single colonoscopy tend to show chronic
inflammation (with or without neutrophils), including in the
rectal mucosa, which introduces difficulties in differentiating
between CD and UC. In such a case, the presence of areas
with inflammation alternating with areas with much less (or
without) inflammation each of the multiple colonic biopsies
should be noted, since focal distribution of inflammation is
highly suggestive of CD. The frequency of granulomas is
higher in children than in adults [86, 87].
In addition, in paediatric patients with CD upper gastroin-
testinal involvement is more frequent than in adults [88]. In
paediatric patients, focal inflammation may be found in the
oesophagus, the stomach, and the duodenum (Fig. 5e, f) [89].
520 Virchows Arch (2014) 464:511–527
However, focal inflammation of the upper gastrointestinal
tract does not exclusively occur in CD, as focally enhanced
gastritis is observed in children with UC [90]. In particular,
although Helicobacter pylori-negative focally enhanced gas-
tritis is more common in children with CD (43–76 %), the
lesion is also seen in UC (8–21 %) [91–95]. Granulomas are
only found in CD [96]. Finally, according to recent literature
data, children with focally enhanced gastritis are about 15
times more likely to have IBD, particularly CD, than non-
IBD controls, proving this type of gastritis to be a valuable
finding in cases of indefinite diagnosis [95].
Interaction between infection and inflammatory bowel
disease
The interaction between infection and IBD is complex:
Infections have been associated with the onset of IBD, but
they might also trigger flare-ups of the disease or a relapse of
symptoms and thus complicate the clinical picture [97].
Moreover, infectious forms of colitis, e.g. tuberculosis, have
to be considered in the differential diagnosis, particularly in
developing countries.
Testing for reactivation of latent CMV infection should be
performed in all patients with severe colitis refractory to
immunosuppressive therapy [98, 99]. In addition, testing
should be performed on biopsies with prominent granulation
tissue associated with large ulcers [98, 100]. In UC, the risk of
CMV reactivation is significantly higher than in CD (10–
56.7 % vs. 0–29.6 %) [101]. The risk depends also on the
type of immunosuppressive drugs used and is higher in
steroid-refractory than in steroid-responsive patients (25–
30 % vs. 0–9.5 %) [99, 101].
Although inclusion bodies indicative of a CMV infection
can be detected in H&E-stained slides, immunohistochem-
istry or molecular techniques are more sensitive and have a
high diagnostic accuracy (Fig. 6a, b) [101]. On H&E-
stained sl ides, CMV typically presents as large
(cytomegalic) cells of (mainly) mesenchymal origin, e.g.
endothelial cells and fibroblasts in granulation tissue. These
are typically two- to fourfold larger than normal, with large
amphophilic intranuclear inclusions, surrounded by a clear
halo, and smaller cytoplasmic inclusions. However, some
infected cells are morphologically less characteristic and
the morphology of ganglion cells and necrotic or apoptotic
cells may resemble CMV inclusions. Due to sampling error,
however, false-negative biopsies are common and in stud-
ies the sensitivity of detection ranges from 10 to 87 %
[101]. Immunohistochemistry, using monoclonal antibod-
ies directed against CMV immediate early antigen, in-
creases the diagnostic yield in comparison with H&E stain-
ing [98, 102] and its sensitivity approximates 93 % [103].
Semiquantitative immunohistochemistry, reporting the
number of infected cells and/or the number of CMV-
positive biopsy fragments, may have a predictive value
[100, 104, 105]. The qualitative polymerase chain reaction
(PCR) can also be used on biopsy tissue to detect viral
DNA, although the significance of a positive result in the
absence of histological features of infection remains un-
clear. Quantitative real-time PCR may be more accurate in
differentiating between infection and disease, but a univer-
sally accepted cut-off value has not been defined [106].
Histology does not allow reliable detection of bacterial
superinfection of the small or large intestine. This holds true
especially for Clostridium difficile infection, as the histologi-
cally characteristic pseudomembranous colitis is usually not
Fig. 6 Cytomegalovirus
detection in inflammatory bowel
disease: comparison of H&E (a,
original magnification, ×200) and
immunohistochemistry (IHC) (b,
original magnification, ×200) in
serial sections, unequivocally
positive cells detected by H&E
are circled. These cells are also
seen in IHC. In addition, several
other infected cells are visible by
IHC only (arrows)
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present in IBD patients treated with immunosuppressive
agents [107–109].
Dysplasia and cancer
Patients with IBD carry an increased risk of colorectal cancer
[110–113]. The most important risk factors are young age at
onset, long disease duration and extensive large bowel in-
volvement, indicating a cumulative effect of intestinal inflam-
mation (dysplasia–carcinoma sequence). Additional risk fac-
tors include primary sclerosing cholangitis, severe inflamma-
tion, polypoid mucosal lesions and a family history of colo-
rectal cancer [113–116].
Although the increased risk is well established for patients
with UC, the less abundant data available for CD indicates
similar risk, given a similar duration and extent of disease
[116–119]. In addition, in CD an increased risk of small bowel
adenocarcinoma exists, most commonly in the distal jejunum
and ileum [120–123].
Dysplasia is the best and most reliable marker of increased
risk of malignancy in patients with IBD [111, 125]. It is
defined as ‘histologically unequivocal neoplastic epithelium
without evidence of tissue invasion’ [124]. For diagnostic
purposes, the dysplasia concept comprises of four distinct
categories: negative for dysplasia (regenerating epithelium),
indefinite for dysplasia (‘questionable’ dysplasia) and positive
for low- or high-grade dysplasia [126]. Inter-observer agree-
ment is poor for low-grade dysplasia and indefinite for
Fig. 7 Flat dysplasia in ulcerative
colitis with marked nuclear
hyperchromasia and
pleomorphism (a, original
magnification, ×100). The lesion
is positive for p53 upon
immunohistochemistry (b,
original magnification, ×100).
Raised or elevated dysplastic non
adenoma-like (colitis-associated)
lesion with irregular neoplastic
glands (varying configuration,
size and diameter) and varying
amounts of stroma (c, original
magnification, ×75). Note
dysplastic goblet cells (d, original
magnification, ×150)
Table 3 Microscopic and clinical features used for the differential diagnosis of neoplastic lesions in inflammatory bowel disease
Colitis-associated dysplasia Adenoma-like lesion (sporadic adenoma)
Age <50 years >60 years
Extent of disease Usually total Usually subtotal
Activity of disease Usually active Usually inactive
Disease duration Long (>10 years) Short (<10 years)
Associated flat dysplasia Common (no sharp delineation) Absent (sharp delineation)
Histology of lesion Irregular neoplastic glands (varying configuration,
size and diameter) with varying amounts of stroma
Regular neoplastic glands (similar configuration,
size and diameter) with low amounts of stroma
Increased (mononuclear) lamina
propria inflammation
Usually present Usually absent
Mixture of benign/dysplastic crypts at surface Usually present Usually absent
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dysplasia [127–130]. Confirmation of dysplasia by a pathol-
ogist with expertise in gastrointestinal pathology has been
recommended by the ECCO/ESP Consensus panel (based
upon similar recommendations for Barrett’s oesophagus)
[3,131].
Dysplasia related to IBD develops only in areas with
chronic inflammation in any part of the colorectum and is
often multifocal [111, 125]. Microscopic features used for
diagnosis are analogous to those characterising neoplasia, in
general, including both architectural and cytological abnor-
malities [126].
There are two distinct macroscopic patterns of dysplastic
lesions in patients with IBD: flat and elevated. According to
the American Gastroenterological Association technical re-
view on the diagnosis andmanagement of colorectal neoplasia
in IBD [113], the term flat dysplasia refers to lesions that are
endoscopically undetectable, whereas elevated dysplasia re-
fers to endoscopically detectable lesions. It should be noted,
however, that the term ‘flat dysplasia’ has also been used to
describe endoscopically detectable, but only slightly raised
lesions (Fig. 7a, b). Hence, flat dysplasia is generally detected
in random biopsies from endoscopically unremarkable muco-
sa. It carries a high risk for cancer: in cases in which flat high-
grade dysplasia had been diagnosed, a synchronous adenocar-
cinoma was found in 42–67 % of cases [113, 132].
Elevated or raised dysplastic lesions are a heterogeneous
group including adenoma- and non-adenoma-like lesions
(Fig. 7c, d) [133, 134]. Non-adenoma-like lesions can appear
as large velvety patches, irregular plaques, irregular bumps
and nodules, wart-like lesions, large sessile polypoid lesions
with a broad base or even as localised strictures [133, 135].
Adenoma-like lesions are usually well circumscribed and
small, sometimes sessile similar to some sporadic adenomas
unrelated to UC. Several clinical and microscopic features
help to differentiate colitis-associated dysplasia from
adenoma-like lesions (Table 3) [70, 133, 136, 137]. The
distinction is important as the clinical management differs
significantly, ranging from local therapy (polypectomy) to
proctocolectomy. According to a recent large retrospective
analysis of patients undergoing proctocolectomy for dyspla-
sia, patients with high-grade dysplasia had cancer in 29 %,
compared to 3 % for patients with low-grade dysplasia. In
addition, patients with elevated non-adenoma-like dysplasia
had cancer in 25 %, compared to 8 % for patients with flat
dysplasia. Hence, the cancer risk of patients with a diagnosis
of high-grade dysplasia or elevated non-adenoma-like dyspla-
sia is substantial, and the threshold for surgery should be low
given the high likelihood of finding cancer in the correspond-
ing resection specimen [3, 138, 139].
Recent studies have focussed on ancillary methods to im-
prove inter-observer variability in detecting dysplasia. The
p53 tumour suppressor gene is a key factor in the initial steps
of IBD-associated carcinogenesis [140]. p53 protein is
overexpressed in 33–67 % of patients with dysplasia and in
83–95 % of patients with IBD-associated carcinomas [141,
142]. However, occasional p53 protein expression in
regenerating non-dysplastic epithelium limits the diagnostic
value of this marker.
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